
Opinion|Videos|August 5, 2024
Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
A panel of experts discuss combination regimens with BTK inhibitors.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- What emerging evidence is there for combination therapies of BTK inhibitors with new and existing therapies to enhance treatment efficacy in CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5